ATTO insider trading — Attovia Therapeutics, Inc.
Over the last 90 days, insiders at Attovia Therapeutics, Inc. (ATTO) made 7 open-market purchases worth $42.08M and 1 open-market sale worth $2.25M, making them net buyers by $39.83M. The largest purchase was by Frazier Life Sciences Xi, L.P., Fhmls Xi, L.P., Fhmls Xi, L.L.C. (10% Owner), who bought 588,235 shares for $10.00M on Aug 6, 2026. The largest sale was by Walsh Colin (Director), who sold 105,807 shares for $2.25M on Aug 5, 2026. 5 different insiders bought shares in this period — a cluster buy, which many investors watch closely.
Updated Oct 16, 2026.
Recent ATTO insider transactions
Every Form 4 filed by Attovia Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Walsh Colin | Director | C · Conversion | Indirect | 2,435,632 | — | — | Form 4 |
| Aug 6, 2026 | Walsh Colin | Director | P · Purchase | Indirect | 500,000 | $17.00 | $8.50M | Form 4 |
| Aug 5, 2026 | Walsh Colin | Director | P · Purchase | Indirect | 85,000 | $21.00 | $1.78M | Form 4 |
| Aug 5, 2026 | Walsh Colin | Director | S · Sale | Indirect | 105,807 | $21.28 | $2.25M | Form 4 |
| Aug 6, 2026 | Goldman Sachs Group Inc, Goldman Sachs & Co. Llc, Goldman Sachs Asset Management, L.P., Broad Street Principal Investments, L.L.C., Wsls Offshore Investments, Slp, West Street Life Sciences I, L.P., Wsls Emp Offshore Investments, L.P., Wsls Emp Onshore Investments, L.P. | - | C · Conversion | Indirect | 2,435,632 | — | — | Form 4 |
| Aug 6, 2026 | Goldman Sachs Group Inc, Goldman Sachs & Co. Llc, Goldman Sachs Asset Management, L.P., Broad Street Principal Investments, L.L.C., Wsls Offshore Investments, Slp, West Street Life Sciences I, L.P., Wsls Emp Offshore Investments, L.P., Wsls Emp Onshore Investments, L.P. | - | P · Purchase | Indirect | 500,000 | $17.00 | $8.50M | Form 4 |
| Aug 5, 2026 | Goldman Sachs Group Inc, Goldman Sachs & Co. Llc, Goldman Sachs Asset Management, L.P., Broad Street Principal Investments, L.L.C., Wsls Offshore Investments, Slp, West Street Life Sciences I, L.P., Wsls Emp Offshore Investments, L.P., Wsls Emp Onshore Investments, L.P. | - | P · Purchase | Indirect | 85,000 | $21.00 | $1.78M | Form 4 |
| Aug 5, 2026 | Goldman Sachs Group Inc, Goldman Sachs & Co. Llc, Goldman Sachs Asset Management, L.P., Broad Street Principal Investments, L.L.C., Wsls Offshore Investments, Slp, West Street Life Sciences I, L.P., Wsls Emp Offshore Investments, L.P., Wsls Emp Onshore Investments, L.P. | - | S · Sale | Indirect | 105,807 | $21.28 | $2.25M | Form 4 |
| Aug 6, 2026 | Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, Lp, Kroin David | 10% Owner | C · Conversion | Direct | 1,957,138 | — | — | Form 4 |
| Aug 6, 2026 | Venbio Global Strategic Fund Iv, L.P. | 10% Owner | C · Conversion | Direct | 3,799,015 | — | — | Form 4 |
| Aug 6, 2026 | Venbio Global Strategic Fund Iv, L.P. | 10% Owner | P · Purchase | Direct | 382,352 | $17.00 | $6.50M | Form 4 |
| Aug 6, 2026 | Redmile Group, Llc, Green Jeremy, Redmile Biopharma Investments Iii, L.P. | 10% Owner | C · Conversion | Indirect | 782,854 | — | — | Form 4 |
| Aug 6, 2026 | Redmile Group, Llc, Green Jeremy, Redmile Biopharma Investments Iii, L.P. | 10% Owner | P · Purchase | Direct | 200,000 | $17.00 | $3.40M | Form 4 |
| Aug 6, 2026 | Redmile Group, Llc, Green Jeremy, Redmile Biopharma Investments Iii, L.P. | 10% Owner | P · Purchase | Indirect | 400,000 | $17.00 | $6.80M | Form 4 |
| Aug 6, 2026 | Sanofi | 10% Owner | C · Conversion | Indirect | 782,855 | — | — | Form 4 |
| Aug 6, 2026 | Sanofi | 10% Owner | P · Purchase | Indirect | 300,000 | $17.00 | $5.10M | Form 4 |
| Aug 6, 2026 | Frazier Life Sciences Xi, L.P., Fhmls Xi, L.P., Fhmls Xi, L.L.C. | 10% Owner | C · Conversion | Direct | 5,490,629 | — | — | Form 4 |
| Aug 6, 2026 | Frazier Life Sciences Xi, L.P., Fhmls Xi, L.P., Fhmls Xi, L.L.C. | 10% Owner | P · Purchase | Direct | 588,235 | $17.00 | $10.00M | Form 4 |
ATTO insider trading FAQ
Are insiders buying ATTO stock?
Yes. In the last 90 days, Attovia Therapeutics, Inc. insiders made 7 open-market purchases totaling $42.08M, and 1 open-market sale totaling $2.25M. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading ATTO?
Recent buyers: Frazier Life Sciences Xi, L.P., Fhmls Xi, L.P., Fhmls Xi, L.L.C., Redmile Group, Llc, Green Jeremy, Redmile Biopharma Investments Iii, L.P., Sanofi, Venbio Global Strategic Fund Iv, L.P., Walsh Colin. Recent sellers: Walsh Colin.
Where does ATTO insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.